Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Leukemia volume 31, pages 771–772 (2017)Cite this article

Subjects

Correspondence on ‘European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia’ by Steegmann et al.1

We read with interest the recent European LeukemiaNet recommendations for the management and avoidance of adverse events (AEs) of treatment in chronic myeloid leukaemia (CML)1 (the recommendations). While the review proposes an exhaustive and critical summary of AEs emerging during CML treatment, we feel that an involvement of cardiovascular (CV) specialists on the panel of members could have deepened the review and balanced the consensus, especially with regards to cardiac and vascular AEs. This correspondence is aiming at providing insights on the potential risks of CV events (CVEs) in patients with CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.

    Article  CAS  Google Scholar 

  2. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.

    Article  CAS  Google Scholar 

  3. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.

    Article  CAS  Google Scholar 

  4. Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89: 732–742.

    Article  CAS  Google Scholar 

  5. Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014; 124: 3135.

    Google Scholar 

  6. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.

    Article  CAS  Google Scholar 

  7. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.

    Article  CAS  Google Scholar 

  8. Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013; 42 (9 Pt 2): e303–e310.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Nathalie Ross, Science and Medical Writer, funded by Novartis Pharmaceuticals for contributing to the writing and editing of this Correspondence. Novartis had no influence on the content of this document.

Author information

Authors and Affiliations

  1. Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada

    C Constance

  2. Department of Medicine, Université de Montréal, Montreal, QC, Canada

    C Constance

  3. Division of Internal Medicine, Jewish General Hospital, Montreal, QC, Canada

    L Trudeau

  4. Montreal Heart Institute, Montreal, QC, Canada

    E M Jolicoeur

  5. Center for Pulmonary Vascular Disease and Division of Cardiology, Jewish General Hospital, Montreal, QC, Canada

    D Langleben

  6. Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada

    A Rivard

  7. Centre intégré de cancérologie de la Montérégie, Hôpital Charles-LeMoyne, Quebec, QC, Canada

    R Chehayeb

  8. CHU de Québec - Hôpital du Saint-Sacrement, Greenfield Park, QC, Canada

    M-A Côté

  9. University Health Network, Toronto, ON, Canada

    D Delgado

Authors
  1. C Constance
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Trudeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E M Jolicoeur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Langleben
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Rivard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Chehayeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-A Côté
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Constance.

Ethics declarations

Competing interests

Dr Christian Constance has received honorarium and support for clinical trials from Astra, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Dr David Langleben has received honoraria and support for clinical trials from Actelio, Bayer, Eiger Biophamaceuticals, Ikaria, Northern Therapeutics, Novartis and United Therapeutics. He has served on advisory boards for Actelion, Bayer, Ikaria, Northern Therapeutics, Novartis, UCB Celltech and United Therapeutics. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Constance, C., Trudeau, L., Jolicoeur, E. et al. Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 31, 771–772 (2017). https://doi.org/10.1038/leu.2016.336

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.336

This article is cited by

Search

Advanced search

Quick links